Web Results

en.wikipedia.org/wiki/SmithKline_Corp._v._Eli_Lilly_%26_Co.

SmithKline Corp. v. Eli Lilly and Co. is a 1978 decision of the United States Court of Appeals for the Third Circuit that first considered the price-discounting practice now termed bundling. Bundling is the setting of the total price of a purchase of several products or services from one seller at a lower level than the sum of the ...

law.justia.com/cases/federal/appellate-courts/ca11/16-11537/16-11537-2017-07-21.html

Jul 21, 2017 ... Jenny Martin v. Eli Lilly & Co., et al, No. 16-11537 (11th Cir. 2017) case opinion from the US Court of Appeals for the Eleventh Circuit.

www.justice.gov/civil/cpb/case/us-v-eli-lilly-and-company-zyprexa

Oct 24, 2014 ... On January 15, 2009, the Assistant Attorney General for the Civil Division and Acting United States Attorney in Philadelphia announced a criminal information and a civil settlement involving pharmaceutical company Eli Lilly and Company. The case involves off-label marketing of Eli Lilly's drug Zyprexa for ...

www.justice.gov/civil/cpb/case/us-v-eli-lilly-and-company-evista

Oct 24, 2014 ... American pharmaceutical manufacturer Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista, the Justice Department announced on December 21 , 2005. In pleading guilty to a criminal count of violating the Food, Drug, ...

www.casebriefs.com/blog/law/intellectual-property-law/intellectual-property-keyed-to-merges/patent-law-intellectual-property-keyed-to-merges/ariad-pharmaceuticals-inc-v-eli-lilly-co

Citation. Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 2010 U.S. App. LEXIS 5966, 94 U.S.P.Q.2D (BNA) 1161 (Fed. Cir. Mar. 22, 2010) Brief Fact. ... The claims were genus claims, including the use of all materials that achieve the desired result of reducing the binding of NF-kB to NF-kB recognition sites.